Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion type Assertion NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_head.
- NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion description "[The glucose-lowering effects of glucagon peptide antagonists and antiglucagon neutralising antibodies first demonstrated the potential of glucagon receptor (GCGR) antagonism as a treatment for hyperglycaemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_provenance.
- NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion evidence source_evidence_literature NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_provenance.
- NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion SIO_000772 15948676 NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_provenance.
- NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion wasDerivedFrom befree-20140225 NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_provenance.
- NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_assertion wasGeneratedBy ECO_0000203 NP917641.RAU0O8cfeHhDHXWY7EWrG03s5vtoJ00t42zTnGnzPSyZU130_provenance.